Actinogen Medical Ltd (ATGGF) Stock Price, Trades & News

Actinogen Medical Ltd is a biotechnology company. The company develops a novel therapy for neurological and neuropsychiatric diseases associated with dysregulated cortisol in the brain. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia.

Financial Strength

Name	Current	Vs Industry
Cash-To-Debt	29.29
Equity-to-Asset	0.79
Debt-to-Equity	0.03
Debt-to-EBITDA	-0.01
Piotroski F-Score	3/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year FCF Growth Rate	15.7
	3-Year Book Growth Rate	-18.3
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	-27.69

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	0.33
	9-Day RSI	2.56
	14-Day RSI	5.7
	3-1 Month Momentum %	-98
	6-1 Month Momentum %	-98
	12-1 Month Momentum %	-96

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.19
	Quick Ratio	4.19
	Cash Ratio	3.12

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	-18.8
	Shareholder Yield %	-1.49

Profitability Rank

	Name	Current	Vs Industry		Vs History
	ROE %	-106.03
	ROA %	-88.79
	ROIC %	-778.97
	3-Year ROIIC %	2223.48
	ROC (Joel Greenblatt) %	-5297.51
	ROCE %	-103.83
	Moat Score	2

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PB Ratio	10.67
	EV-to-EBIT	-6.35
	EV-to-EBITDA	-6.51
	EV-to-Forward-EBITDA	-3.44
	EV-to-Forward-Revenue	11.15
	EV-to-FCF	-6.85
	Earnings Yield (Greenblatt) %	-15.75
	FCF Yield %	-13.83

GF Value™

ATGGF

Warning Signs

Warning! GuruFocus detected 4 Severe warning signs with ATGGF. Try a 7-Day Free Trial to check it out.

Actinogen Medical Ltd Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Actinogen Medical Ltd Stock Events

Financials Calendars

	Event	Date	Price ($)
No Event Data

Guru Commentaries on OTCPK:ATGGF

No articles.

Press Release

	Subject	Date
	Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states	2025-08-27
	A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US	2025-07-22
	Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline	2025-06-30
	Actinogen announces peer-reviewed clinical pharmacology manuscript for Xanamem (emestedastat) published in Clinical Pharmacology in Drug Development journal	2025-02-12
	Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem	2025-02-05
	Actinogen randomizes first US participant in XanaMIA phase 2b/3 Alzheimer's disease trial	2024-12-09
	Actinogen announces further positive results on depression in the XanCIDD phase 2a trial	2024-08-26
	Actinogen announces achievement of clinically and statistically significant superiority of Xanamem® over placebo on depression in XanaCIDD phase 2a trial	2024-08-12
	Positive Xanamem® biomarker trial published in the Journal of Alzheimer's Disease demonstrating potential Xanamem efficacy in patients with elevated blood pTau	2024-06-26
	Enrolment completed in Actinogen's XanaCIDD phase 2a cognition & depression trial	2024-04-22

10/Page

Articles on Actinogen Medical Ltd

No articles.

Headlines

No news.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.